Emerging therapies in castrate-resistant prostate cancer

Luai Zarour, Joshi Alumkal

    Research output: Contribution to journalReview articlepeer-review

    14 Scopus citations


    Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivation therapy, also known as hormonal therapy. In recent years, an increased understanding of molecular mechanisms of prostate cancer progression and castration resistance has led to improved treatment strategies. This review focuses on emerging therapies for the treatment of castrate-resistant prostate cancer, with an emphasis on the importance of the drug targets as well as the state of current clinical trials, including those utilizing hormonal therapies, biological agents, and immunotherapy that are underway or have recently been completed.

    Original languageEnglish (US)
    Pages (from-to)152-158
    Number of pages7
    JournalCurrent urology reports
    Issue number3
    StatePublished - May 2010


    • Castration-resistant
    • Prostate cancer

    ASJC Scopus subject areas

    • Urology


    Dive into the research topics of 'Emerging therapies in castrate-resistant prostate cancer'. Together they form a unique fingerprint.

    Cite this